Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (23)

II-17Peter Bloomingdale

An Artificial Intelligence Framework for Optimal Drug Design

Wednesday 15:35-17:00

II-20Thomas Bouillon

Comparison and selection of dosing regimens by discretization, optimizing efficacy and evaluating exposure demonstrated for KAE609 (Cipargamin)

Wednesday 15:35-17:00

II-24Simona Catozzi

Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin

Wednesday 15:35-17:00

II-32Jared Cui

Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects

Wednesday 15:35-17:00

II-55Janice Goh

A translational toolkit to predict clinical Phase IIb/III outcomes from preclinical mouse studies

Wednesday 15:35-17:00

II-59Sofia Guzzetti

An integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions

Wednesday 15:35-17:00

II-60Chihiro Hasegawa

Exploring simplification of a target-mediated drug disposition (TMDD) model for bispecific antibodies for potential application to data-driven modelling

Wednesday 15:35-17:00

II-66Vijay Ivaturi

Novel convolution-based In vitro-In vivo correlation (IVIVC) model with time scaling and bioavailability sub-models for, JORNAY PM®, a methylphenidate hydrochloride delayed-release and extended-release capsule

Wednesday 15:35-17:00

II-70Woojin Jung

Fractal kinetic implementation in population modeling

Wednesday 15:35-17:00

II-77Niklas Korsbo

DeepPumas for automatic discovery of individualizable functions governing longitudinal patient outcomes

Wednesday 15:35-17:00

II-78Anis Krache

Modelling selective cell targeting through avidity to inform bispecific antibody discovery and development

Wednesday 15:35-17:00

II-80Jialin Mao

Shared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds

Wednesday 15:35-17:00

II-81Francois Mercier

Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models

Wednesday 15:35-17:00

IV-12Raphaela Schenk

How to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition

Thursday 15:25-16:55

IV-39Sebastian Micluța-Câmpeanu

Automatic model discovery in Quantitative Systems Biology

Thursday 15:25-16:55

IV-56Morgane PHILIPP

Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis

Thursday 15:25-16:55

IV-59Fatiha Rachedi

Predicting Motor function scores using uHex4 biomarker effect in Pompe disease

Thursday 15:25-16:55

IV-60Christopher Rackauckas

Robust Parameter Estimation of Rational Ordinary Differential Equations for NLME and QSP

Thursday 15:25-16:55

IV-61Christopher Rackauckas

Uncertainty quantified discovery of chemical reaction systems via Bayesian scientific machine learning

Thursday 15:25-16:55

IV-67Soroush Safaei

Developing a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates

Thursday 15:25-16:55

IV-74Sebastiaan Sassen

The importance of model selection for a priori model informed precision dosing of vancomycin

Thursday 15:25-16:55

IV-78Marie Steinacker

Non-linear autoregressive exogenous modelling to predict individual haematotoxicity during chemotherapy

Thursday 15:25-16:55

IV-94Daichi Yamaguchi

Population pharmacokinetic modelling for vancomycin using Bayesian model averaging approach

Thursday 15:25-16:55